Skip to main content
      Late-Breaking Trials in axSpA and PsA https://t.co/Fw8wiAPLoN

      The amazing @Janetbirdope discussing head to head trial

      Nouf Al hemmadi NoufAhmedAlham2

      4 months 1 week ago
      Late-Breaking Trials in axSpA and PsA https://t.co/Fw8wiAPLoN The amazing @Janetbirdope discussing head to head trials in Axial SpA and PsA with primary failure to TNF. To switch to another TNF or IL17? IL17 for my PsA patient for sure. @RheumNow #ACR25
      #ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development w

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development which binds to pan-gamma delta T-cell instead of CD3 to minimise risk of cytokine release syndrome side effect. Abstr#1535 @RheumNow https://t.co/MOmUm41cyA https://t.co/TgIUGgWGw5
      Two new studies presented this year tackle a key question: can our initial treatment choices influence who ends up in the difficult-to-treat category?
      Axial spondyloarthritis (axSpA) remains a diagnostic challenge, particularly in its early stages before structural sacroiliitis is visible on imaging.
      New Paradigms in RA Treatment
      🎥 LIVE from #ACR25
      Join us daily at 5 PM CST for RheumNow’s ACR Recap Live -
      Your must-watch debrief of the day’

      Dr. John Cush RheumNow

      4 months 1 week ago
      🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live - Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways. Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live. Save the time. Be part of https://t.co/ZgZM14L6ta
      #ACR25 Please find my video interview with Prof Edward Vital @edvital on their work on International Consensus of Glucoc

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Please find my video interview with Prof Edward Vital @edvital on their work on International Consensus of Glucocorticoid Tapering Guideline in #SLE #lupus Abstr#1526 @RheumNow https://t.co/MnQdcdASkG https://t.co/b7GMcnFU2m
      #ACR25 Please find my video and take on Abstr#0646. Promising new Bi-specific T-cell engager (BiTE) other than Blinatumo

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Please find my video and take on Abstr#0646. Promising new Bi-specific T-cell engager (BiTE) other than Blinatumomab in #SLE @RheumNow https://t.co/5JrLG41nsD https://t.co/KeY6AkHUNK
      #ACR25 Please find my video and take on Abstr#0803. Should we use Belimumab before- or after a trial of concentional imm

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Please find my video and take on Abstr#0803. Should we use Belimumab before- or after a trial of concentional immunosuppressant in #SLE? @RheumNow https://t.co/ExIvrdJXw5 https://t.co/AVb5ohWwXZ
      SLGT-2 and GLP-1 in RA: More than Weight Loss https://t.co/SRKMHNlHZo

      Future of rheumatology is bright , Shreya Sakthi

      Nouf Al hemmadi NoufAhmedAlham2

      4 months 1 week ago
      SLGT-2 and GLP-1 in RA: More than Weight Loss https://t.co/SRKMHNlHZo Future of rheumatology is bright , Shreya Sakthivel discussed her work on TriNetX database , looking specifically for effect of SLGT-2. GLP-1 on RA flare incidence. @RheumKay @RheumNow #acr25
      ×